Screening and identification of potential MERS-CoV papain-like protease (PLpro) inhibitors; Steady-state kinetic and Molecular dynamic studies
Authors:
- Mohammed Ali DahhasMDMohammed Ali Dahhas
- Hamad M. AlkahtaniHAHamad M. Alkahtani
- Ajamaluddin MalikAMAjamaluddin Malik
- Abdulrahman A AlmehiziaAAAbdulrahman A Almehizia
- Ahmed H. BakheitAhmed H. Bakheit
- Siddique Akber AnsarSASiddique Akber Ansar
- Abdullah S. AlAbdulkarimAAAbdullah S. AlAbdulkarim
- Lamees S.ALrasheedLSLamees S.ALrasheed
- Mohammad A. AlsenaidyMAMohammad A. Alsenaidy
Open Access
- 16 December 2022
- journal article
- research article
- Published by Springer Nature in Saudi Pharmaceutical Journal
- Vol. 31 (2) , 228-244
Abstract
MERS-CoV belongs to the coronavirus group. Recent years have seen a rash of coronavirus epidemics. In June 2012, MERS-CoV was discovered in the Kingdom of Saudi Arabia, with 2,591 MERSA cases confirmed by lab tests by the end of August 2022 and 894 deaths at a case-fatality ratio (CFR) of 34.5% documented worldwide. Saudi Arabia reported the majority of these cases, with 2,184 cases and 813 deaths (CFR: 37.2%), necessitating a thorough understanding of the molecular machinery of MERS-CoV. To develop antiviral medicines, illustrative investigation of the protein in coronavirus subunits are required to increase our understanding of the subject. In this study, recombinant expression and purification of MERS-CoV (PLpro), a primary goal for the development of 22 new inhibitors, were completed using a high throughput screening methodology that employed fragment-based libraries in conjunction with structure-based virtual screening. Compounds 2, 7, and 20, showed significant biological activity. Moreover, a docking analysis revealed that the three compounds had favorable binding mood and binding free energy. Molecular dynamic simulation demonstrated the stability of compound 2 (2-((Benzimidazol-2-yl) thio)-1-arylethan-1-ones) the strongest inhibitory activity against the PLpro enzyme. In addition, disubstitutions at the meta and para locations are the only substitutions that may boost the inhibitory action against PLpro. Compound 2 was chosen as a MERS-CoV PLpro inhibitor after passing absorption, distribution, metabolism, and excretion studies; however, further investigations are required.Keywords
This publication has 63 references indexed in Scilit:
- Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4Cell Research, 2013
- Cell Host Response to Infection with Novel Human Coronavirus EMC Predicts Potential Antivirals and Important Differences with SARS CoronavirusmBio, 2013
- The Spike Protein of the Emerging Betacoronavirus EMC Uses a Novel Coronavirus Receptor for Entry, Can Be Activated by TMPRSS2, and Is Targeted by Neutralizing AntibodiesJournal of Virology, 2013
- Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in HumansmBio, 2012
- CHARMM: The biomolecular simulation programJournal of Computational Chemistry, 2009
- Protonate3D: Assignment of ionization states and hydrogen coordinates to macromolecular structuresProteins: Structure, Function, and Bioinformatics, 2009
- Protein production and purificationNature Methods, 2008
- Severe acute respiratory syndrome coronavirus papain-like protease: Structure of a viral deubiquitinating enzymeProceedings of the National Academy of Sciences, 2006
- Scalable molecular dynamics with NAMDJournal of Computational Chemistry, 2005
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996